Physician profile
Talia Nelson
NPI 1336502681
$1,421.01
in general payments reported to CMS, 2019-2025
12 companies · $428 in 2025
The $428 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $204 · 2022: $221 · 2023: $462 · 2024: $106 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $996.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $251.18 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $241.83 | 2023-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Lilly USA, LLC | $222.01 | 2023 | Mounjaro, Jardiance |
| Teva Pharmaceuticals USA, INC. | $125.01 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $124.92 | 2021 | |
| Gilead Sciences, INC. | $121.89 | 2025 | Yeztugo |
| Grifols USA, LLC | $95.82 | 2022 | |
| Kyowa Kirin, INC. | $91.04 | 2024 | |
| Sunovion Pharmaceuticals INC. | $78.85 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $26.22 | 2025 | Rejoyn |
| Abbvie INC. | $25.82 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.42 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Talia Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.